Abstract: OBJECTIVE To investigate the clinical efficacy of Danlou tablet in Non-revascularization Patients with acute coronary syndrome (ACS)and phlegm and blood stasis syndrome type(PBSST). METHODS 70 ACS patients with PBSST for various reasons failed revascularization therapy were randomly assigned to the control group and the treatment group. The control group was given a standardized western medicine treatment and the treatment group was given Danlou tablets (every time 1.5g， 3 times a day) based on standardized western medicine treatment for a month. Angina episodes (intensity， frequency， duration)， nitroglycerin use (consumption， angina relief time after taking nitroglycerin ) and the score of angina， traditional Chinese Medicine（TCM）clinical syndrome (including: chest pain or tightness and its frequency and duration， palpitations， shortness of breath， fatigue and total syndrome score)， lipids including total cholesterol (TC)， low-density lipoprotein cholesterol (LDL-C)， high density lipoprotein cholesterol (HDL-C)， triglycerides (TG) and hypersensitive C-reactive protein (hs-CRP) were observed in the two groups of patients before and after treatment. The clinical efficacy of angina，the score of TCM clinical syndrome and blood biochemical changes were recorded and compared between the two groups. RESULT The total effective rate of angina (85.29%) was significantly better than that of the control group (48.48%)(P<0.01). Compared with the same group before treatment， the frequency and duration of angina， the angina relief time after taking nitroglycerin， the amount of nitroglycerin， the score of angina and TCM clinical syndromes and the total score of syndrome，all these were significantly lower (P<0.01) in the two groups of patients after treatment. Compared with the control group， the frequency and duration of angina， the angina relief time after taking nitroglycerin， the amount of nitroglycerin， the total score of TCM clinical syndrome (P<0.05) and the score of angina (P<0.01) were significantly lower in the treatment group after treatment. The improvement of TCM clinical syndromes in the treatment group (the total efficiency of syndrome score was 79.41%) was significantly better than the control group (the total efficiency of syndrome score was 45.45%) (P<0.01). TC， LDL-C(P<0.01) and hs-CRP (P<0.05) levels after treatment were significantly lower than before. After treatment， hs-CRP in the treatment group was significantly lower compared with the control group(P<0.05). CONCLUSION Danlou tablet can promote a significant improvement to angina and TCM clinical syndromes in Non-revascularization Patients with ACS and PBSST， inhibit the inflammation， and show plaque stabilizing effects.